This study is a single blind, clinical trial that evaluates the effects of Spinal-z on patients with metastatic gastric adenocarcinoma. The Patients who enter this study are between 15 and 65 years old and they have received pathologic diagnosis of gastric adenocarcinoma (stage 4). The Patients with creatinine over than 2 or Ejection Fraction less than 45%, are excluded from the study. About 78 patients are evaluated in this study. The patients are divided randomly interventional and control. The patients do not know about 2 group interventional and control (single blind). The patients in interventional group are treated by 6 Spinal-z capsules daily (2 capsules after breakfast, 2 capsules after lunch and 2 capsules after dinner). The control group is treated by 6 capsules of placebo in the same order. There is no difference between placebo and spinal-z capsules in shape, weight, color, taste and odor. The patients are visited and evaluated once every three weeks for 3 months. The patients are evaluated for digestive signs (dysphagia, abdominal pain and anorexia), itching, nausea, vomiting, Blood urea nitrogen, creatinine, fasting blood sugar, blood pressure, heart rate, hemoglobin, platelets, white blood cells, and their liver enzymes are evaluated every 6 weeks. Digestive signs scale from 0 to 10 score and according to this scaling, patients are divided to, mild (1-3), moderate (4-6), severe (7-10) and zero (0). The patients are excluded from the study in case of exposure to severe complications, or disagreement to carry on the study.